论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Jiang K, Shen M, Xu W
Received 22 November 2017
Accepted for publication 16 March 2018
Published 27 April 2018 Volume 2018:13 Pages 2561—2569
DOI https://doi.org/10.2147/IJN.S157746
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Govarthanan Muthusamy
Peer reviewer comments 3
Editor who approved publication: Dr Linlin Sun
Purpose: In
this study, a novel arginine, glycine, aspartic acid peptide (RGD)-modified
paclitaxel and curcumin co-loaded liposomes were developed to evaluate their
antitumor activity in vitro and in vivo.
Materials and
methods: Co-loaded liposomes were prepared
using the solvent evaporation method. The particles had spherical shapes under
electron microscopy with sizes <130 nm.
Results: By comparison with the free drug, RGD-modified paclitaxel and
curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded liposomes
have sustained-release properties in vitro. In vivo, there was no significant
difference in pharmacokinetic parameters between the RGD-modified paclitaxel
and curcumin co-loaded liposomes and paclitaxel and curcumin co-loaded
liposomes. A strong green fluorescence was observed in the cytoplasmic region
after incubation of RGD-modified paclitaxel and curcumin co-loaded liposomes
for 2 h. RGD-modified paclitaxel and curcumin co-loaded liposomes showed a
superior antiproliferative effect on A549 cells with a possible mechanism that
suppressed the multidrug resistance phenomenon and exhibited a clear synergistic
effect.
Conclusion: The results indicate that RGD-modified paclitaxel and curcumin
co-loaded liposomes had a better antitumor effect in vivo than the non-modified
LPs. These results indicate that RGD-modified co-loaded liposomes are a
promising candidate for antitumor drug delivery.
Keywords: arginine, glycine, aspartic acid peptide, paclitaxel, curcumin,
liposome, cell uptake, cytotoxicity study, in vivo anti-tumor study